Abstracts tagged "interstitial lung disease"

Abstract Number: 1780 • 2016 ACR/ARHP Annual Meeting
Pulmonary Disease in Late Versus Early Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Jennifer Medlin¹, Karen Hansen², Sara McCoy³ and Christie M. Bartels⁴, ¹Internal Medicine, University of Wisconsin Hospitals and Clinics, Madison, WI, ²Department of Medicine, Division of Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI, ³Department of Medicine, Rheumatology Division, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Medicine, Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Phenotypes often differ in late-onset systemic lupus erythematosus (SLE) compared to SLE features in early-onset patients. Prior studies have suggested that there may be…
Abstract Number: 274 • 2016 ACR/ARHP Annual Meeting
Splicing Factor Proline/Glutamine-Rich Is a Novel Autoantigen of Dermatomyositis and Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibody.
Yuji Hosono¹, Ran Nakashima¹, Kosaku Murakami¹, Yoshitaka Imura¹, Satoshi Serada², Minoru Fujimoto³, Hajime Yoshifuji¹, Koichiro Ohmura⁴, Tetsuji Naka⁵ and Tsuneyo Mimori⁴, ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Laboratory for Immune Signal, National Institute of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan, ³Laboratry of immune signal, National Institute of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan, ⁴Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁵Laboratory for immune signal, National Institute of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan
Background/Purpose: Anti- melanoma differentiation-associated gene 5 (MDA5) antibody positive dermatomyositis (DM) and clinically amyopathic DM (CADM) often develop rapidly progressive interstitial lung disesase (RP-ILD),…
Abstract Number: 1880 • 2016 ACR/ARHP Annual Meeting
A Large Proportion of Patients in an Early Systemic Sclerosis-Associated Interstitial Lung Disease Cohort Have Coexisting Pulmonary Hypertension
Amber Young¹, Caitlyn Fisher¹, Rajaie Namas², Holly Wilhalme³ and Dinesh Khanna⁴, ¹Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Department of Medicine [Division of Rheumatology], University of Michigan, Ann Arbor, MI, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic Sclerosis (SSc) is a multi-organ system disease manifested by fibrosis, vascular damage and dysregulation of the immune system. The leading causes of death…
Abstract Number: 823 • 2016 ACR/ARHP Annual Meeting
A Phase 2 Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness in Subjects with Systemic Sclerosis with Interstitial Lung Disease
Vivien Hsu¹, Christopher P.Denton², Robyn T. Domsic³, Daniel E. Furst⁴, Maureen Rischmueller⁵, Marina Stanislav⁶, Virginia D. Steen⁷, Douglas Hough⁸, Shimon Korish⁹, Alyse Cooper¹⁰, Peter H. Schafer¹¹ and Suktae Choi¹², ¹Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ, ²Centre of Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ³Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁵University of Adelaide, Adelaide, Australia, ⁶Research Rheumatology Institute n. a. V.A. Nassonova, Moscow, Russia, ⁷Rheumatology, Georgetown University Medical Center, Washington, DC, ⁸Clinical Research, Celgene Corporation, Warren, NJ, ⁹33 Technology Drive, Celgene Corporation, Warren, NJ, ¹⁰Immunology & Inflammation, Clinical Research, Celgene Corporation, Summit, NJ, ¹¹Department of Translational Development, Celgene Corporation, Summit, NJ, ¹²Biostatistics, Celgene Corporation, Summit, NJ
Background/Purpose: Pomalidomide (POM) is an IMiD compound, structurally similar to thalidomide. POM binds to cereblon and facilitates Ikaros and Aiolos degradation, resulting in immunomodulation of…
Abstract Number: 1884 • 2016 ACR/ARHP Annual Meeting
Esophageal Dilation and Interstitial Lung Disease Incidence and Progression in Systemic Sclerosis
Kimberly Showalter¹, Aileen Hoffmann², Carrie Richardson^3,4, Julia (Jungwha) Lee⁵, David Aaby⁶, Rishi Agrawal⁷, Jane Dematte⁸, Rowland W. Chang⁹ and Monique Hinchcliff¹⁰, ¹Internal Medicine, McGaw Medical Center of Northwestern University, Chicago, IL, ²Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Northwestern University, Chicago, IL, ³Department of Medicine, McGaw Medical Center of Northwestern University, Chicago, IL, ⁴Department of Rheumatology, Johns Hopkins University, Baltimore, MD, ⁵Preventive Medicine/Biostatistics, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Northwestern University Feinberg School of Medicine, Chicago, IL, ⁷Radiology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁸Pulmonology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁹Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁰Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in systemic sclerosis (SSc). Esophageal dysfunction and aspiration may play a role in SSc-ILD.…
Abstract Number: 824 • 2016 ACR/ARHP Annual Meeting
Mycophenolate Versus Placebo for the Treatment of Systemic Sclerosis-Related Interstitial Lung Disease
Elizabeth R. Volkmann¹, Donald P. Tashkin², Ning Li³, Michael Roth⁴, Dinesh Khanna⁵, Anna-Maria Hoffmann-Vold⁶, Philip J. Clements⁴, Daniel E. Furst¹, Robert Elashoff⁷ and Scleroderma Lung Study II Group, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ³UCLA, Los Angeles, CA, ⁴Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵University of Michigan, Ann Arbor, MI, ⁶Oslo University Hospital, Oslo, Norway, ⁷Biomathematics, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Compared with placebo, treatment with cyclophosphamide (CYC) improved lung function and dyspnea in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD).1 While treatment with…
Abstract Number: 2019 • 2016 ACR/ARHP Annual Meeting
Faces in Motion: Clinical Subtyping in Scleroderma Using Changes in Forced Vital Capacity
Colin Ligon¹, Peter Schulam², Suchi Saria³, Fredrick M. Wigley⁴, Robert Wise⁵ and Laura K. Hummers⁶, ¹Rheumatology, University of Pennsylvania School of Medicine, Philadelphia, PA, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁴Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Department of Pulmonology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Prognostication in scleroderma has historically depended on using static measures such as antibody status and extent of skin involvement to stratify risk of mortality…
Abstract Number: 825 • 2016 ACR/ARHP Annual Meeting
KL-6 and Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis Related Interstitial Lung Disease
Gloria Salazar¹, Masataka Kuwana², Minghua Wu¹, Jun Ying¹, Julio Charles³, Maureen D Mayes¹ and Shervin Assassi¹, ¹Department of Internal Medicine - Rheumatology, University of Texas-McGovern Medical School, Houston, TX, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Internal Medicine-Rheumatology, University of Texas-McGovern Medical School, Houston, TX
Background/Purpose: Pneumoproteins are attractive biomarker candidates in systemic sclerosis (SSc) related interstitial lung disease (ILD) because they are easily obtainable and lung-specific. KL-6 and CCL-18…
Abstract Number: 2310 • 2016 ACR/ARHP Annual Meeting
The Predictive Risk Factors for Complication of Infection during the Treatment for Inflammatory Myopathies Complicated with Interstitial Lung Disease
Yumiko SUGIYAMA^1,2, Maasa Tamura^1,2,3, Ryusuke Yoshimi^1,2, Naoki Hamada^1,2, Hideto Nagai^1,2, Yuko Tatekabe^1,2, Naomi Tsuchida^2,4, Yutaro Soejima^1,2, Yosuke Kunishita^2,4, Daiga Kishimoto^1,2, Hiroto Nakano^1,2, Reikou Kamiyama^1,2, Kaoru Minegishi^2,5, Yukiko Asami^1,2, Yohei Kirino^2,4, Shigeru Ohno^2,5 and Hideaki Nakajima¹, ¹Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Y-CURD Study Group, Yokohama, Japan, ³Nagaoka Red Cross Hospital, Nagaoka, Japan, ⁴Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan, ⁵Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan
Background/Purpose: Interstitial lung disease (ILD) is one of the predominant causes of death in polymyositis/dermatomyositis (PM/DM). We have already reported that low PaCO2 and interstitial…
Abstract Number: 830 • 2016 ACR/ARHP Annual Meeting
Cardiopulmonary Disease Development in Anti-RNA Polymerase III Positive Systemic Sclerosis; Comparative Analyses from an Unselected, Prospective Patient Cohort
Anna Hoffmann-Vold¹, Anders Heiervang Tennøe², Oyvind Midtvedt², May Brit Lund³, Torhild Garen², Fadi El-Hage⁴, Trond Mogens Aalokken⁵, Eli Taraldsrud⁴ and Øyvind Molberg², ¹Division of Rheumatology, Oslo University Hospital, Oslo, Norway, ²Rheumatology, Oslo University Hospital, Oslo, Norway, ³Respiratory Medicine, Oslo University Hospital, Oslo, Norway, ⁴Oslo University Hospital, Oslo, Norway, ⁵Radiology, Oslo University Hospital, Oslo, Norway
Background/Purpose: Extensive skin disease and renal crisis are hallmarks of anti-RNA polymerase III (RNAP) positive systemic sclerosis (SSc), while data on lung and heart involvement…
Abstract Number: 2311 • 2016 ACR/ARHP Annual Meeting
Initial Predictors of Short-Term Poor Survival Rates in Patients with Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease
Shinji Sato¹, Kenichi Masui², Naoshi Nishina³, Yasushi Kawaguchi⁴, Atsushi Kawakami⁵, Maasa Tamura⁶, Kei Ikeda⁷, Takahiro Nunokawa⁸, Yoshinori Tanino⁹, Katsuaki Asakawa¹⁰, Yuko Kaneko¹¹, Takahisa Gono¹², Masataka Kuwana³ and JAMI investigators, ¹Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan, ²Department of Anesthesiology, National Defense Medical College School of Medicine, Tokorozawa, Japan, ³Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁶Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁷Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan, ⁸Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ⁹Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan, ¹⁰Division of Respiratory Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan, ¹¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹²Department of Rheumatology, Jichi Medical University Saitama Medical Center, Saitama, Japan
Background/Purpose: Polymyositis (PM)/dermatomyositis (DM) is a chronic inflammatory disorder that affects muscle, skin and lung in various degree, and interstitial lung disease (ILD) is a…
Abstract Number: 831 • 2016 ACR/ARHP Annual Meeting
Immunosuppression May Prevent Interstitial Lung Disease in Systemic Sclerosis
Sabrina Hoa¹, Marie Hudson², Mianbo Wang³, Russell Steele⁴, Murray Baron⁵ and Canadian Scleroderma Research Group, ¹Division of Rheumatology, Jewish General Hospital, Lady Davis Institute, Montreal, QC, Canada, ²Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, QC, Canada, ³Lady Davis Institute for Medical Research, Montreal, QC, Canada, ⁴Mathematics, McGill University, Montreal, QC, Canada, ⁵Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of premature mortality in systemic sclerosis (SSc). Immunosuppression is used for treatment of established disease. However,…
Abstract Number: 2565 • 2016 ACR/ARHP Annual Meeting
Common Biomarker Elevations in Idiopathic Pulmonary Fibrosis and Rheumatoid Arthritis-Associated Interstitial Lung Disease
Karen Fernandez¹, Tracy Doyle², Lisa Harlow³, Ivan O. Rosas⁴ and Dana P. Ascherman⁵, ¹Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ²Medicine/Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, ³Rheumatology and Clinical Immunology, University of Miami Miller School of Medicine, Miami, FL, ⁴BWH - Pulmonary, Brigham and Women's Hospital, Boston, MA, ⁵Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL
Background/Purpose: Interstitial lung disease (ILD) is an extra-articular manifestation of rheumatoid arthritis (RA) which contributes to increased morbidity and mortality. Clinico-epidemiological data indicate some overlap…
Abstract Number: 1590 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Arthritis-Related Interstitial Lung Disease (RA-ILD): Methotrexate and the Extension of Lung Disease Are Associated to Prognosis
Jorge Rojas-Serrano¹, Denisse Herrera-Bringas², Renzo Perez-Dorame³, Mayra Mejia² and Heidegger Mateos-Toledo⁴, ¹Interstitial Lung Diseases Unit, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, ²Interstitial Lung Diseases Unit, Insituto Nacional de Enfermedades Respiratorias, Mexico, Mexico, ³Intertitial Lung Disease Unit, Instituto Nacional de Enfermedades Respiratorias, Mexico, Mexico, ⁴Interstitial Lung Diseases Unit, Instituto Nacional de Enfermedades Respiratorias, Mexico, Mexico
Background/Purpose:Interstitial lung disease (ILD) is a severe rheumatoid arthritis manifestation with a median survival of 2.6 years. Worst survival has been associated to usual interstitial…
Abstract Number: 1882 • 2015 ACR/ARHP Annual Meeting
The Predictive Value of Pulmonary Function Tests to Diagnose Interstitial Lung Disease in Adults with Early Diffuse Cutaneous Systemic Sclerosis
Elana J. Bernstein¹, Veronica J. Berrocal², Virginia D. Steen³, Victoria K. Shanmugam^4,5, Ami A. Shah⁶, Monique E. Hinchcliff⁷, Faye N. Hant⁸, Jessica K. Gordon⁹, Tracy M. Frech¹⁰, Robyn T. Domsic¹¹, Shervin Assassi¹² and Dinesh Khanna¹³, ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Div of Rheumatology, University of Michigan, Ann Arbor, MI, ³Rheumatology, Georgetown University Medical Center, Washington, DC, ⁴Division of Rheumatology, The George Washington University, Washington, DC, ⁵Director, Division of Rheumatology, The George Washington University, Washington, DC, ⁶Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Rheumatology, Northwestern University, Chicago, IL, ⁸Dept of Medicine, Medical University of South Carolina, Charleston, SC, ⁹Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁰Div of Rheumatology, University of Utah, Salt Lake City, UT, ¹¹Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹²Rheumatology, University of Texas Medical School at Houston, Houston, TX, ¹³Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc). Patients with diffuse cutaneous systemic sclerosis (dcSSc) have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].